Clinical Trial Update: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Avelumab (avelumab)
• Combination chemotherapy
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)
• Utomilumab (utomilumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED